Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CVAC
- Price
- 3.12
- Stock movement down
- -0.08 (-2.50%)
- Company name
- CureVac NV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 699.93M
- Ent value
- 278.56M
- Price/Sales
- 1.29
- Price/Book
- 0.97
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 6.46
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 17.07%
- 3 year return
- -43.71%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CVAC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 6.46 |
| Price to OCF | 5.61 |
| Price to FCF | 4.91 |
| Price to EBITDA | 3.07 |
| EV to EBITDA | 1.22 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.29 |
| Price to Book | 0.97 |
| EV to Sales | 0.51 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 224.34M |
| EPS (TTM) | 0.48 |
| FCF per share (TTM) | 0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 543.28M |
| Gross profit (TTM) | 385.34M |
| Operating income (TTM) | 132.33M |
| Net income (TTM) | 108.29M |
| EPS (TTM) | 0.48 |
| EPS (1y forward) | -0.51 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 70.93% |
| Operating margin (TTM) | 24.36% |
| Profit margin (TTM) | 19.93% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 550.86M |
| Net receivables | 20.80M |
| Total current assets | 584.72M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 854.19M |
| Accounts payable | 13.42M |
| Short/Current long term debt | 40.13M |
| Total current liabilities | 94.35M |
| Total liabilities | 129.49M |
| Shareholder's equity | 724.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 124.81M |
| Capital expenditures (TTM) | 30.28M |
| Free cash flow (TTM) | 142.63M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 14.94% |
| Return on Assets | 12.68% |
| Return on Invested Capital | 14.84% |
| Cash Return on Invested Capital | 19.54% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.15 |
| Daily high | 3.16 |
| Daily low | 3.07 |
| Daily Volume | 283K |
| All-time high | 136.27 |
| 1y analyst estimate | 7.24 |
| Beta | 2.61 |
| EPS (TTM) | 0.48 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 May 2025 |
Downside potential
Loading...
Downside potential data
| CVAC | S&P500 | |
| Current price drop from All-time high | -97.71% | -14.12% |
| Highest price drop | -98.30% | -56.47% |
| Date of highest drop | 25 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -78.04% | -11.07% |
| Avg time to new high | 147 days | 12 days |
| Max time to new high | 1094 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
699.93M
Marketcap category
Small-cap
Description
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Employees
999
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page